Advertisement

Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

Published:January 12, 2022DOI:https://doi.org/10.1016/j.bpsc.2021.12.012

      Abstract

      Background

      Major depressive disorder (MDD) is associated with various cognitive impairments, including response inhibition. Deficits in response inhibition may also underlie poor antidepressant treatment response. Recent studies revealed that the neurobiological correlates of response inhibition can predict response to pharmacological treatments. However, the generalizability of this finding to first-line nonpharmacological treatments, particularly cognitive behavioral therapy, remains to be investigated.

      Methods

      Data from two independent treatment protocols were combined, one in which 65 patients with MDD underwent treatment with escitalopram, and the other in which 41 patients with MDD underwent a course of cognitive behavioral therapy. A total of 25 healthy control subjects were also recruited. Neural correlates of response inhibition were captured by participants completing a Go/NoGo task during electroencephalography recording. Response inhibition–related measures of interest included the amplitudes of the N2 and P3 event-related potentials.

      Results

      Pretreatment P3 amplitude, which has been linked to both the motor and cognitive aspects of response inhibition, was a significant predictor of change in depressive symptoms following escitalopram and cognitive behavioral therapy treatment. A greater pretreatment P3 amplitude was associated with a greater reduction in depressive severity. In addition, the pretreatment P3 amplitude was found to be significantly greater at baseline in remitters than in nonremitters and healthy control subjects.

      Conclusions

      The integrity of response inhibition may be critical for a successful course of pharmacological or psychological treatment for MDD. Electrophysiological correlates of response inhibition may have utility as a general prognostic marker of treatment response in MDD. Future studies may investigate the benefit of preceding first-line treatments with interventions that improve response inhibition in MDD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Shilyansky C.
        • Williams L.M.
        • Gyurak A.
        • Harris A.
        • Usherwood T.
        • Etkin A.
        Effect of antidepressant treatment on cognitive impairments associated with depression: A randomised longitudinal study.
        Lancet Psychiatry. 2016; 3: 425-435
        • Trivedi M.H.
        • Greer T.L.
        Cognitive dysfunction in unipolar depression: Implications for treatment.
        J Affect Disord. 2014; 152–154: 19-27
        • Roiser J.P.
        • Sahakian B.J.
        Hot and cold cognition in depression.
        CNS Spectr. 2013; 18: 139-149
        • Lam R.W.
        • Kennedy S.H.
        • Mclntyre R.S.
        • Khullar A.
        Cognitive dysfunction in major depressive disorder: Effects on psychosocial functioning and implications for treatment.
        Can J Psychiatry. 2014; 59: 649-654
        • Cuijpers P.
        • Berking M.
        • Andersson G.
        • Quigley L.
        • Kleiboer A.
        • Dobson K.S.
        A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments.
        Can J Psychiatry. 2013; 58: 376-385
        • Cipriani A.
        • Furukawa T.A.
        • Salanti G.
        • Chaimani A.
        • Atkinson L.Z.
        • Ogawa Y.
        • et al.
        Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis.
        Lancet. 2018; 391: 1357-1366
        • Parikh S.V.
        • Quilty L.C.
        • Ravitz P.
        • Rosenbluth M.
        • Pavlova B.
        • Grigoriadis S.
        • et al.
        Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 2. Psychological treatments.
        Can J Psychiatry. 2016; 61: 524-539
        • Snyder H.R.
        Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review.
        Psychol Bull. 2013; 139: 81-132
        • Diamond A.
        Executive functions.
        Annu Rev Psychol. 2013; 64: 135-168
        • Disner S.G.
        • Beevers C.G.
        • Haigh E.A.P.
        • Beck A.T.
        Neural mechanisms of the cognitive model of depression.
        Nat Rev Neurosci. 2011; 12: 467-477
        • Gohier B.
        • Ferracci L.
        • Surguladze S.A.
        • Lawrence E.
        • El Hage W.
        • Kefi M.Z.
        • et al.
        Cognitive inhibition and working memory in unipolar depression.
        J Affect Disord. 2009; 116: 100-105
        • Joormann J.
        • Gotlib I.H.
        Emotion regulation in depression: Relation to cognitive inhibition.
        Cogn Emot. 2010; 24: 281-298
        • Eugène F.
        • Joormann J.
        • Cooney R.E.
        • Atlas L.Y.
        • Gotlib I.H.
        Neural correlates of inhibitory deficits in depression.
        Psychiatry Res. 2010; 181: 30-35
        • Ruchsow M.
        • Groen G.
        • Kiefer M.
        • Beschoner P.
        • Hermle L.
        • Ebert D.
        • Falkenstein M.
        Electrophysiological evidence for reduced inhibitory control in depressed patients in partial remission: A go/nogo study.
        Int J Psychophysiol. 2008; 68: 209-218
        • Clawson A.
        • Clayson P.E.
        • Larson M.J.
        Cognitive control adjustments and conflict adaptation in major depressive disorder.
        Psychophysiology. 2013; 50: 711-721
        • Kaiser R.H.
        • Andrews-Hanna J.R.
        • Spielberg J.M.
        • Warren S.L.
        • Sutton B.P.
        • Miller G.A.
        • et al.
        Distracted and down: Neural mechanisms of affective interference in subclinical depression.
        Soc Cogn Affect Neurosci. 2015; 10: 654-663
        • Vanderhasselt M.A.
        • De Raedt R.
        • Dillon D.G.
        • Dutra S.J.
        • Brooks N.
        • Pizzagalli D.A.
        Decreased cognitive control in response to negative information in patients with remitted depression: An event-related potential study.
        J Psychiatry Neurosci. 2012; 37: 250-258
        • Langenecker S.A.
        • Kennedy S.E.
        • Guidotti L.M.
        • Briceno E.M.
        • Own L.S.
        • Hooven T.
        • et al.
        Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder.
        Biol Psychiatry. 2007; 62: 1272-1280
        • Gyurak A.
        • Patenaude B.
        • Korgaonkar M.S.
        • Grieve S.M.
        • Williams L.M.
        • Etkin A.
        Frontoparietal activation during response inhibition predicts remission to antidepressants in patients with major depression.
        Biol Psychiatry. 2016; 79: 274-281
        • Tozzi L.
        • Goldstein-Piekarski A.N.
        • Korgaonkar M.S.
        • Williams L.M.
        Connectivity of the cognitive control network during response inhibition as a predictive and response biomarker in major depression: Evidence from a randomized clinical trial.
        Biol Psychiatry. 2020; 87: 462-472
        • Crane N.A.
        • Jenkins L.M.
        • Bhaumik R.
        • Dion C.
        • Gowins J.R.
        • Mickey B.J.
        • et al.
        Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI.
        Brain. 2017; 140: 472-486
        • Etkin A.
        • Patenaude B.
        • Song Y.J.C.
        • Usherwood T.
        • Rekshan W.
        • Schatzberg A.F.
        • et al.
        A cognitive-emotional biomarker for predicting remission with antidepressant medications: A report from the iSPOT-D trial.
        Neuropsychopharmacology. 2015; 40: 1332-1342
        • Hofmann S.G.
        • Asnaani A.
        • Vonk I.J.J.
        • Sawyer A.T.
        • Fang A.
        The efficacy of cognitive behavioral therapy: A review of meta-analyses.
        Cognit Ther Res. 2012; 36: 427-440
        • Kennedy S.H.
        • Lam R.W.
        • Rotzinger S.
        • Milev R.V.
        • Blier P.
        • Downar J.
        • et al.
        Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: A CAN-BIND-1 report.
        J Clin Psychiatry. 2019; 80: 18m12202
        • Huster R.J.
        • Enriquez-Geppert S.
        • Lavallee C.F.
        • Falkenstein M.
        • Herrmann C.S.
        Electroencephalography of response inhibition tasks: Functional networks and cognitive contributions.
        Int J Psychophysiol. 2013; 87: 217-233
        • Falconer E.
        • Allen A.
        • Felmingham K.L.
        • Williams L.M.
        • Bryant R.A.
        Inhibitory neural activity predicts response to cognitive-behavioral therapy for posttraumatic stress disorder.
        J Clin Psychiatry. 2013; 74: 895-901
        • Cipriani A.
        • Santilli C.
        • Furukawa T.A.
        • Signoretti A.
        • Nakagawa A.
        • McGuire H.
        • et al.
        Escitalopram versus other antidepressive agents for depression.
        Cochrane Database Syst Rev. 2009; 2: CD006532
        • Kennedy S.H.
        • Andersen H.F.
        • Lam R.W.
        Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: A meta-analysis [published correction appears in J Psychiatry Neurosci 2006; 31:228].
        J Psychiatry Neurosci. 2006; 31: 122-131
        • Montgomery S.A.
        • Åsberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Lam R.W.
        • Milev R.
        • Rotzinger S.
        • Andreazza A.C.
        • Blier P.
        • Brenner C.
        • et al.
        Discovering biomarkers for antidepressant response: Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
        BMC Psychiatry. 2016; 16: 105
        • Leucht S.
        • Fennema H.
        • Engel R.R.
        • Kaspers-Janssen M.
        • Szegedi A.
        Translating the HAM-D into the MADRS and vice versa with equipercentile linking.
        J Affect Disord. 2018; 226: 326-331
        • Berman R.M.
        • Fava M.
        • Thase M.E.
        • Trivedi M.H.
        • Swanink R.
        • McQuade R.D.
        • et al.
        Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
        CNS Spectr. 2009; 14: 197-206
        • Lenze E.J.
        • Mulsant B.H.
        • Blumberger D.M.
        • Karp J.F.
        • Newcomer J.W.
        • Anderson S.J.
        • et al.
        Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: A randomised, double-blind, placebo-controlled trial [published correction appears in Lancet 2015; 386:2394].
        Lancet. 2015; 386: 2404-2412
        • Worthington 3rd, J.J.
        • Kinrys G.
        • Wygant L.E.
        • Pollack M.H.
        Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.
        Int Clin Psychopharmacol. 2005; 20: 9-11
        • Beck A.T.
        • Rush A.J.
        • Shaw B.F.
        • Emery G.
        Cognitive Therapy of Depression.
        Guilford Press, New York1979
        • Blackburn I.M.
        • James I.A.
        • Milne D.L.
        • Baker C.
        • Standart S.
        • Garland A.
        • Reichelt F.K.
        The revised cognitive therapy scale (CTS-R): Psychometric properties.
        Behav Cogn Psychother. 2001; 29: 431-446
        • Farzan F.
        • Atluri S.
        • Frehlich M.
        • Dhami P.
        • Kleffner K.
        • Price R.
        • et al.
        Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: Insights from the Canadian biomarker integration network in depression.
        Sci Rep. 2017; 7: 7473
        • Delorme A.
        • Makeig S.
        EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis.
        J Neurosci Methods. 2004; 134: 9-21
        • Kappenman E.S.
        • Luck S.J.
        Best practices for event-related potential research in clinical populations.
        Biol Psychiatry Cogn Neurosci Neuroimaging. 2016; 1: 110-115
        • Trivedi M.H.
        • Rush A.J.
        • Wisniewski S.R.
        • Nierenberg A.A.
        • Warden D.
        • Ritz L.
        • et al.
        Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: Implications for clinical practice.
        Am J Psychiatry. 2006; 163: 28-40
        • Fournier J.C.
        • DeRubeis R.J.
        • Shelton R.C.
        • Hollon S.D.
        • Amsterdam J.D.
        • Gallop R.
        Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression.
        J Consult Clin Psychol. 2009; 77: 775-787
        • Vickers A.J.
        The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: A simulation study.
        BMC Med Res Methodol. 2001; 1: 6
        • Hawley C.J.
        • Gale T.M.
        • Sivakumaran T.
        • Hertfordshire Neuroscience Research group
        Defining remission by cut off score on the MADRS: Selecting the optimal value.
        J Affect Disord. 2002; 72: 177-184
        • Tadel F.
        • Baillet S.
        • Mosher J.C.
        • Pantazis D.
        • Leahy R.M.
        Brainstorm: A user-friendly application for MEG/EEG analysis.
        Comput Intell Neurosci. 2011; 2011: 879716
        • Kennedy S.H.
        • Downar J.
        • Evans K.R.
        • Feilotter H.
        • Lam R.W.
        • MacQueen G.M.
        • et al.
        The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in response prediction.
        Curr Pharm Des. 2012; 18: 5976-5989
        • Uher R.
        • Tansey K.E.
        • Malki K.
        • Perlis R.H.
        Biomarkers predicting treatment outcome in depression: What is clinically significant?.
        Pharmacogenomics. 2012; 13: 233-240
        • Groom M.J.
        • Cragg L.
        Differential modulation of the N2 and P3 event-related potentials by response conflict and inhibition.
        Brain Cogn. 2015; 97: 1-9
        • Donkers F.C.L.
        • van Boxtel G.J.M.
        The N2 in go/no-go tasks reflects conflict monitoring not response inhibition.
        Brain Cogn. 2004; 56: 165-176
        • Enriquez-Geppert S.
        • Konrad C.
        • Pantev C.
        • Huster R.J.
        Conflict and inhibition differentially affect the N200/P300 complex in a combined go/nogo and stop-signal task.
        Neuroimage. 2010; 51: 877-887
        • Smith J.L.
        • Johnstone S.J.
        • Barry R.J.
        Movement-related potentials in the Go/NoGo task: The P3 reflects both cognitive and motor inhibition.
        Clin Neurophysiol. 2008; 119: 704-714
        • Smith J.L.
        • Jamadar S.
        • Provost A.L.
        • Michie P.T.
        Motor and non-motor inhibition in the go/nogo task: An ERP and fMRI study.
        Int J Psychophysiol. 2013; 87: 244-253
        • Gajewski P.D.
        • Falkenstein M.
        Effects of task complexity on ERP components in go/nogo tasks.
        Int J Psychophysiol. 2013; 87: 273-278
        • Polich J.
        Updating P300: An integrative theory of P3a and P3b.
        Clin Neurophysiol. 2007; 118: 2128-2148
        • Drysdale A.T.
        • Grosenick L.
        • Downar J.
        • Dunlop K.
        • Mansouri F.
        • Meng Y.
        • et al.
        Resting-state connectivity biomarkers define neurophysiological subtypes of depression [published correction appears in Nat Med 2017; 23:264].
        Nat Med. 2017; 23: 28-38
        • Williams L.M.
        Precision psychiatry: A neural circuit taxonomy for depression and anxiety.
        Lancet Psychiatry. 2016; 3: 472-480
        • Houben K.
        • Nederkoorn C.
        • Wiers R.W.
        • Jansen A.
        Resisting temptation: Decreasing alcohol-related affect and drinking behavior by training response inhibition.
        Drug Alcohol Depend. 2011; 116: 132-136
        • Lawrence N.S.
        • O’Sullivan J.
        • Parslow D.
        • Javaid M.
        • Adams R.C.
        • Chambers C.D.
        • et al.
        Training response inhibition to food is associated with weight loss and reduced energy intake.
        Appetite. 2015; 95: 17-28
        • Zhao X.
        • Chen L.
        • Maes J.H.R.
        Training and transfer effects of response inhibition training in children and adults.
        Dev Sci. 2018; 21
        • Sahdra B.K.
        • MacLean K.A.
        • Ferrer E.
        • Shaver P.R.
        • Rosenberg E.L.
        • Jacobs T.L.
        • et al.
        Enhanced response inhibition during intensive meditation training predicts improvements in self-reported adaptive socioemotional functioning.
        Emotion. 2011; 11: 299-312
        • Echiverri-Cohen A.
        • Spierer L.
        • Perez M.
        • Kulon M.
        • Ellis M.D.
        • Craske M.
        Randomized-controlled trial of response inhibition training for individuals with PTSD and impaired response inhibition.
        Behav Res Ther. 2021; 143: 103885
        • Hartmann L.
        • Sallard E.
        • Spierer L.
        Enhancing frontal top-down inhibitory control with Go/NoGo training.
        Brain Struct Funct. 2016; 221: 3835-3842
        • Benikos N.
        • Johnstone S.J.
        • Roodenrys S.J.
        Short-term training in the go/nogo task: Behavioural and neural changes depend on task demands.
        Int J Psychophysiol. 2013; 87: 301-312
        • Valentine G.
        • Sofuoglu M.
        Cognitive effects of nicotine: Recent progress.
        Curr Neuropharmacol. 2018; 16: 403-414